REDUCTION OF LDL CHOLESTEROL BY PRAVASTATIN DOES NOT INFLUENCE PLATELET ACTIVATION IN PATIENTS WITH MILD HYPERCHOLESTEROLEMIA AT RISK OF CORONARY HEART-DISEASE

被引：17

作者：

BARROW, SE ^{[1
]}

STRATTON, PD ^{[1
]}

BENJAMIN, N ^{[1
]}

BRASSFIELD, T ^{[1
]}

RITTER, JM ^{[1
]}

机构：

[1] BRISTOL MYERS SQUIBB PHARMACEUT,CLIN RES DEPT,HOUNSLOW TW3 3JA,MIDDX,ENGLAND

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 1991年 / 32卷 / 01期

关键词：

THROMBOXANE A2; PLATELET ACTIVATION; PRAVASTATIN; LDL; HYPERCHOLESTEROLEMIA;

D O I：

10.1111/j.1365-2125.1991.tb05625.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The effect of pravastatin on low density lipoprotein (LDL) cholesterol and platelet activation was studied in 16 patients with mild hypercholesterolaemia who had two or more additional cardiovascular risk factors. Patients were treated with either pravastatin (20-40 mg day-1) or placebo for 1 year. Plasma LDL and urinary excretion of 2,3-dinor-thromboxane B2 (an index of platelet activation in vivo) were determined at 0, 3, 6 and 12 months. There was a significant reduction in LDL at 6 and 12 months (2P < 0.05) but this was not associated with any significant change in thromboxane metabolite excretion.

引用

页码：127 / 129

页数：3

共 27 条

[21] Relationship between platelet activation related factors and polymorphism of related genes in patients with coronary heart disease of blood-stasis syndrome
Mei Xue
Ke-ji Chen
Hui-jun Yin
Chinese Journal of Integrative Medicine, 2008, 14 : 267 - 273
[22] Relationship between Platelet Activation Related Factors and Polymorphism of Related Genes in Patients with Coronary Heart Disease of Blood-stasis Syndrome
薛梅
陈可冀
殷惠军
Chinese Journal of Integrative Medicine, 2008, 14 (04) : 267 - 273
[23] Relationship between Platelet Activation Related Factors and Polymorphism of Related Genes in Patients with Coronary Heart Disease of Blood-stasis Syndrome
Xue Mei
Chen Ke-ji
Yin Hui-jun
CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2008, 14 (04) : 267 - 273
[24] Intensively Lowering Both Low-Density Lipoprotein Cholesterol and Blood Pressure Does Not Reduce Cardiovascular Risk in Japanese Coronary Artery Disease Patients
Kohro, Takahide
Yamazaki, Tsutomu
Izumi, Tohru
Daida, Hiroyuki
Kurabayashi, Masahiko
Miyauchi, Katsumi
Tojo, Taiki
Nagai, Ryozo
CIRCULATION JOURNAL, 2011, 75 (09) : 2062 - 2070
[25] Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk
Rosen, Jeffrey B.
Ballantyne, Christie M.
Hsueh, Willa A.
Lin, Jianxin
Shah, Arvind K.
Lowe, Robert S.
Tershakovec, Andrew M.
LIPIDS IN HEALTH AND DISEASE, 2015, 14
[26] Pharmakoökonomische Bewertung von Pravastatin in der Sekundärprävention der koronaren Herzkrankheit bei Patienten mit durchschnittlichen CholesterinwertenEine Analyse für Deutschland auf der Grundlage der CARE-StudiePharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for germany based on the CARE study
Thomas D. Szucs
Georg Guggenberger
Karin Berger
Winfried März
Jürgen R. Schäfer
Herz, 1998, 23 (5) : 319 - 329
[27] Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein
Davidson, Michael H.
Abate, Nicola
Ballantyne, Christie M.
Catapano, Alberico L.
Xu, Xia
Lin, Jianxin
Rosenberg, Elizabeth
Tershakovec, Andrew M.
JOURNAL OF CLINICAL LIPIDOLOGY, 2008, 2 (06) : 436 - 446

← 1 2 3 →